Simon Rolland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simon Rolland has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Florence Galtier
INSERM, CIC 1411, CHU de Montpellier, Hôpital Saint-Eloi, Montpellier, France; INSERM, F-CRIN, I REIVAC, Paris, France
2 shared publications - Liem Binh Luong Nguyen
Université de Paris Cité
2 shared publications - Alexandre Descamps
Inserm CIC 1417, France; CIC Cochin Pasteur, Paris, France
1 shared publication Annabelle Pourbaix
Department of Infectious Diseases, Assistance Publique-Hôpitaux de Paris, Bichat–Claude-Bernard University Hospital, Paris, France
1 shared publication- Anne Sophie L'HOnneur
APHP, Paris, France
1 shared publication Arnaud Fontanet
Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (Supplement) , S93-S100
Characteristics of Human Metapneumovirus Infection Compared to Respiratory Syncytial Virus and Influenza Infections in Adults Hospitalized for Influenza-Like Illness in France, 2012–2022
Background: We aimed to compare the characteristics of human metapneumovirus (hMPV) infection with influenza A and B virus (FLUV) and respiratory syncytial virus (RSV) infections in adults hospitalized with influenza-like illness (ILI). Methods: We conducted a post hoc analysis of adult patients hospitalized with community-acquired ILI who were enrolled in the FLUVAC study at 5 French referral hospitals from 2012 to 2022. Results: At least 1 respiratory virus was detected in 3620 of 6618 patients (55%), including FLUV (1524/3620 [42%]), RSV (248/3620 [7%]), and hMPV (162/3620 [5%]). hMPV+ patients, when compared to FLUV+ patients were more likely to develop at least 1 complication (60% [86/143] vs 50% [716/1435]; P = .02), especially acute heart failure, which occurred twice as often in hMPV+ during the hospital stay (22% [32/143] vs 11% [160/1434]; P < .001). The rates of respiratory (30% [43/143] vs 32% [70/216]; P = .73) or cardiac (22% [32/143] vs 15% [33/216]; P = .09) complications did not differ between hMPV+ and RSV+ patients. The in-hospital all-cause death rate was similar among all 3 populations (4% hMPV+, 4% FLUV+, and 5% RSV+). Conclusions: Hospitalized hMPV infections affect older patients with multiple chronic conditions who face frequent cardiac and pulmonary complications during hospitalization more frequently than with influenza and similar to RSV.
- 15 July 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (Supplement) , S93-S100
Open AccessCharacteristics of Human Metapneumovirus Infection Compared to Respiratory Syncytial Virus and Influenza Infections in Adults Hospitalized for Influenza-Like Illness in France, 2012–2022
Background: We aimed to compare the characteristics of human metapneumovirus (hMPV) infection with influenza A and B virus (FLUV) and respiratory syncytial virus (RSV) infections in adults hospitalized with influenza-like illness (ILI). Methods: We conducted a post hoc analysis of adult patients hospitalized with community-acquired ILI who were enrolled in the FLUVAC study at 5 French referral hospitals from 2012 to 2022. Results: At least 1 respiratory virus was detected in 3620 of 6618 patients (55%), including FLUV (1524/3620 [42%]), RSV (248/3620 [7%]), and hMPV (162/3620 [5%]). hMPV+ patients, when compared to FLUV+ patients were more likely to develop at least 1 complication (60% [86/143] vs 50% [716/1435]; P = .02), especially acute heart failure, which occurred twice as often in hMPV+ during the hospital stay (22% [32/143] vs 11% [160/1434]; P < .001). The rates of respiratory (30% [43/143] vs 32% [70/216]; P = .73) or cardiac (22% [32/143] vs 15% [33/216]; P = .09) complications did not differ between hMPV+ and RSV+ patients. The in-hospital all-cause death rate was similar among all 3 populations (4% hMPV+, 4% FLUV+, and 5% RSV+). Conclusions: Hospitalized hMPV infections affect older patients with multiple chronic conditions who face frequent cardiac and pulmonary complications during hospitalization more frequently than with influenza and similar to RSV.
- Open Access
- 4 February 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 153, 107811
Influenza and pneumococcal vaccine coverage among adults hospitalized with acute respiratory infection in France: A prospective cohort study
- 4 February 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 153, 107811
Open AccessInfluenza and pneumococcal vaccine coverage among adults hospitalized with acute respiratory infection in France: A prospective cohort study
- 26 January 2021
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (5) , 1372-1374
Evolution of practices regarding COVID-19 treatment in France during the first wave: results from three cross-sectional surveys (March to June 2020)
- 26 January 2021
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (5) , 1372-1374
Evolution of practices regarding COVID-19 treatment in France during the first wave: results from three cross-sectional surveys (March to June 2020)
- Top Cited PapersOpen Access
- 2 September 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (559)
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Different serological assays measuring anti–SARS-CoV-2 antibodies and their neutralizing activity in samples from individuals with severe and mild COVID-19 are compared.
- 2 September 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (559)
Top Cited PapersOpen AccessA comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Different serological assays measuring anti–SARS-CoV-2 antibodies and their neutralizing activity in samples from individuals with severe and mild COVID-19 are compared.